Discover
UPB
Upstream Bio, Inc.
7.28
2 x 5.33
2 x 8.83
bid
ask
+
0.36
5.20%
2 @ 05:01 AM
7.33 +0.05 (0.69%)
| Ytd | -73.19% | |
| 1y | -34.59% |
6.81
day range
7.42
5.85
52 week range
33.68
| Open | 6.90 | Prev Close | 6.92 | Low | 6.81 | High | 7.42 | Mkt Cap | 396.18M |
| Vol | 548.44K | Avg Vol | 606.57K | EPS | -2.90 | P/E | N/A | Forward P/E | -2.45 |
| Beta | N/A | Short Ratio | 2.45 | Inst. Own | 94.73% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 7.95 | 200-d Avg | 17.10 | 1yr Est | 47.86 |
UPB News
gurufocus.com
Fannie Mae Announces the Results of its Thirty-sixth Reperforming Loan Sale Transaction
Fannie Mae Announces the Results of its Thirty-sixth Reperforming Loan Sale Transaction PR Newswire
benzinga.com
Reported Sunday, Upstream Bio Presents Phase 2 VIBRANT Data Showing 79% Of Verekitug-Treated CRSwNP
– Verekitug, administered once every three months, led to clinically meaningful improvements in nasa
benzinga.com
JP Morgan Downgrades Upstream Bio to Neutral, Lowers Price Target to $8
JP Morgan analyst Tessa Romero downgrades Upstream Bio (NASDAQ:UPB) from Overweight to Neutral an
benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com
Upstream Bio to Present New Verekitug Data at EAACI 2026, Phase 2 Nasal Polyps Analysis Gets EAACI O
Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory dis
benzinga.com
HC Wainwright & Co. Initiates Coverage On Upstream Bio with Buy Rating, Announces Price Target of $3
HC Wainwright & Co. analyst Matthew Caufield initiates coverage on Upstream Bio (NASDAQ:UPB)